BRIEF published on 01/01/2026 at 07:35, 5 months 26 days ago Evotec nomme Sarah Fakih au poste de vice-présidente exécutive des communications mondiales et des relations avec les investisseurs. Direction Communications Relations Avec Les Investisseurs Evotec Sarah Fakih
BRIEF published on 01/01/2026 at 07:35, 5 months 26 days ago Evotec Appoints Dr. Sarah Fakih as EVP of Global Communications and Investor Relations Investor Relations Leadership Communications Evotec Sarah Fakih
PRESS RELEASE published on 01/01/2026 at 07:30, 5 months 26 days ago Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment Investor Relations Appointment Evotec Global Communications Dr. Sarah Fakih
BRIEF published on 12/08/2025 at 07:05, 6 months 19 days ago Evotec finalise la vente de son site de Toulouse à Sandoz pour 350 millions de dollars. Croissance Des Revenus Licence Technologique Evotec Biosimilaires Sandoz
BRIEF published on 12/08/2025 at 07:05, 6 months 19 days ago Evotec Finalizes Sale of Toulouse Site to Sandoz for $350 Million Revenue Growth Biosimilars Evotec Sandoz Technology License
PRESS RELEASE published on 12/08/2025 at 07:00, 6 months 19 days ago Evotec closes sale of Just – Evotec Biologics’ Toulouse site to Sandoz Evotec closes sale of Just - Evotec Biologics' Toulouse site to Sandoz for over US$650m, including technology license fees. Sale improves revenue mix and profit margins Technology Sale Evotec Sandoz Biologics
BRIEF published on 12/04/2025 at 08:35, 6 months 23 days ago Bayer Initiates Phase 2 Study for Alport Syndrome Treatment with Evotec Clinical Trial Bayer Evotec Alport Syndrome Semaphorin-3A
BRIEF published on 12/04/2025 at 08:35, 6 months 23 days ago Bayer lance une étude de phase 2 pour le traitement du syndrome d'Alport avec Evotec Bayer Essai Clinique Evotec Syndrome D'Alport Sémaphorine-3A
PRESS RELEASE published on 12/04/2025 at 08:30, 6 months 23 days ago Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome Evotec-partner Bayer initiates Phase 2 study for potential Alport syndrome treatment. BAY 3401016 mAb targets Sema3A protein Bayer Evotec Phase 2 Study Alport Syndrome BAY 3401016
BRIEF published on 11/12/2025 at 07:35, 7 months 15 days ago Evotec Secures Milestone Payment from Bristol Myers Squibb FDA Approval Evotec Milestone Payment Bristol Myers Squibb Protein Degradation
Published on 06/27/2026 at 16:50, 1 hour 5 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 16 hours 15 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 17 hours 55 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 18 hours 55 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 19 hours 5 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 17 hours 50 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 17 hours 51 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 18 hours 19 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 18 hours 19 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 18 hours 27 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
